Coins usually have two sides...
Does that mean then that if everyone tries it once they drop the priice, MNKD will own 1/3 of the market?
If this is the case, they will need to build at least another 4 Danbury size plants just to service the US market alone.
Oh yes, and off to Iggistan for you.
It may be as simple as one short clown with 5 to 10 ids reporting your post as Spam. I might even go so far as to suggest that this could be done with a script on a website testing package. We could do a test here and create a post. Every one who participates would give a thumbs up and then report it as spam. We would monitor it to see how many thumbs it reviewed before being deleted. Bet that number is under 10.
Did a quick review of your 35 posts since you spawned your new id and i am going to have to call "FUD".
Off to Iggistan with you, but am looking forwad to a new conversation with you new id next week.
One issue "COST".
I suspect that many users did not have time to dial the usage in correctly, resulting the same A1C readings and when renewal time came around figured that the cozt/benefit was just not there for those that could afford it.
Again, cost seems to bethe current hold back.
The coughing that is the real problem with the renewals is the one patients have when finding out the script renewal price without insurance and the discount card. This will easily be remedied once MNMD gets its baby back and drops the price to parity or below the price of Pens as was their intent before getting sandbagged.
Put this clown and all other ultimate punters on ignore would be a much better decision. Try to do some house keeping just before ignoring though and report the spam.
Anyone care to guess why yazoo can't auto delete this junk?
Have you been warching any of the events surrounding Sanofi and the Sandbagging of "Partnered" products. One partner is before the courts siting intentional delaying of its product in favour of an in house product and the other is Mannkind's Inhaled Insulin that is showing astounding results in early adoptors Sanofi after a year of sitting on its thumbs cut the partnership loose at its earliest allowed breakup date. They sited poor sales but if you look at how they priced it at double the price, it doesn't take much to figure out why they couldn't get insurance coverage and therefore why no one was buying.